Robert Francomano
Nessuna posizione attualmente
Patrimonio netto: 36 355 $ in data 30/04/2024
Profilo
Robert M.
Francomano served as the Chief Commercial Officer at Stemline Therapeutics, Inc. from 2016 to 2021.
He then held the position of Chief Commercial Officer & Senior Vice President at SELLAS Life Sciences Group, Inc. from 2022 to 2024.
Prior to his roles in the pharmaceutical industry, he obtained an undergraduate degree from Siena College and an MBA from the University of Albany.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 22/01/2024 | 23 918 ( 0.04% ) | 36 355 $ | 30/04/2024 |
Precedenti posizioni note di Robert Francomano
| Società | Posizione | Fine |
|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Corporate Officer/Principal | 31/03/2024 |
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2021 |
Formazione di Robert Francomano
| Siena College | Undergraduate Degree |
| University of Albany | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Robert Francomano